Fiduciary Financial Group LLC Boosts Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Fiduciary Financial Group LLC boosted its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 3.9% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,665 shares of the medical research company’s stock after purchasing an additional 63 shares during the quarter. Fiduciary Financial Group LLC’s holdings in Charles River Laboratories International were worth $310,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of CRL. Versant Capital Management Inc increased its holdings in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock valued at $30,000 after buying an additional 150 shares during the last quarter. Wolff Wiese Magana LLC purchased a new position in shares of Charles River Laboratories International during the third quarter worth about $32,000. Assetmark Inc. grew its holdings in shares of Charles River Laboratories International by 1,153.3% during the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after purchasing an additional 173 shares during the last quarter. ORG Wealth Partners LLC purchased a new position in shares of Charles River Laboratories International during the fourth quarter worth about $56,000. Finally, Wilmington Savings Fund Society FSB purchased a new position in shares of Charles River Laboratories International during the third quarter worth about $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the topic of several research reports. UBS Group raised their price objective on Charles River Laboratories International from $240.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. CLSA lowered Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a report on Monday, November 18th. Evercore ISI increased their target price on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research note on Thursday, November 7th. Robert W. Baird decreased their target price on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a research note on Friday, September 20th. Finally, TD Cowen increased their target price on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research note on Monday, November 11th. Three investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $214.00.

Charles River Laboratories International Price Performance

CRL stock opened at $174.37 on Thursday. The firm has a 50 day moving average of $193.36 and a 200-day moving average of $199.12. Charles River Laboratories International, Inc. has a 12-month low of $173.81 and a 12-month high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a market cap of $8.92 billion, a price-to-earnings ratio of 21.82, a PEG ratio of 4.92 and a beta of 1.38.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $975.99 million. During the same period last year, the firm earned $2.72 EPS. The company’s revenue for the quarter was down 1.6% on a year-over-year basis. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Transactions at Charles River Laboratories International

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 1.30% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).